Literature DB >> 25533942

Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer.

Alessia Errico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25533942     DOI： 10.1038/nrclinonc.2014.221

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  3 in total

1.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  3 in total
  27 in total

1.  Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.

Authors:  Motao Zhu; Xilai Ding; Ruifang Zhao; Xuewu Liu; Haifa Shen; Chunmei Cai; Mauro Ferrari; Helen Y Wang; Rong-Fu Wang
Journal:  J Control Release       Date:  2018-01-08       Impact factor: 9.776

Review 2.  Treatment of advanced squamous cell carcinoma of the lung: a review.

Authors:  Benjamin A Derman; Kathryn F Mileham; Philip D Bonomi; Marta Batus; Mary J Fidler
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 3.  Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.

Authors:  N Daaboul; G Nicholas; S A Laurie
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

4.  Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape.

Authors:  Neeraja Dharmaraj; Stacey L Piotrowski; Chen Huang; Jared M Newton; Leonard S Golfman; Aurelie Hanoteau; Sandeep T Koshy; Aileen W Li; Merlyn X Pulikkathara; Bing Zhang; Jared K Burks; David J Mooney; Yu L Lei; Andrew G Sikora; Simon Young
Journal:  Oncoimmunology       Date:  2019-02-06       Impact factor: 8.110

5.  CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.

Authors:  H Zhang; Y-L Ye; M-X Li; S-B Ye; W-R Huang; T-T Cai; J He; J-Y Peng; T-H Duan; J Cui; X-S Zhang; F-J Zhou; R-F Wang; J Li
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

6.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Authors:  Valerie Chew; Liyun Lai; Lu Pan; Chun Jye Lim; Juntao Li; Raymond Ong; Camillus Chua; Jing Yao Leong; Kiat Hon Lim; Han Chong Toh; Ser Yee Lee; Chung Yip Chan; Brian K P Goh; Alexander Chung; Pierce K H Chow; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

7.  Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Authors:  Justin M Balko; Luis J Schwarz; Na Luo; Mónica V Estrada; Jennifer M Giltnane; Daniel Dávila-González; Kai Wang; Violeta Sánchez; Phillip T Dean; Susan E Combs; Donna Hicks; Joseph A Pinto; Melissa D Landis; Franco D Doimi; Roman Yelensky; Vincent A Miller; Phillip J Stephens; David L Rimm; Henry Gómez; Jenny C Chang; Melinda E Sanders; Rebecca S Cook; Carlos L Arteaga
Journal:  Sci Transl Med       Date:  2016-04-13       Impact factor: 17.956

Review 8.  Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.

Authors:  Amber G Bozward; Frazer Warricker; Ye H Oo; Salim I Khakoo
Journal:  Front Immunol       Date:  2021-04-30       Impact factor: 7.561

9.  A Nanoscale Metal-Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy.

Authors:  Kaiyuan Ni; Taokun Luo; Guangxu Lan; August Culbert; Yang Song; Tong Wu; Xiaomin Jiang; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-29       Impact factor: 16.823

10.  The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.

Authors:  Ziying Lin; Yutong Xu; Yaxiong Zhang; Qihua He; Jianrong Zhang; Jianxing He; Wenhua Liang
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.